Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan
Experimental Dermatology · 2024
DOI: 10.1111/exd.15067 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Dermatology, 2024. Verfasst von Yayoi Tada und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie Inc, AbbVie.
Abstract (Originalsprache)
Patients receiving interleukin (IL)‐inhibiting biologics for moderate‐to‐severe psoriasis (PsO) may be treated with escalated doses to optimize outcomes. This study evaluated escalation prevalence in a Japanese claims analysis of patients with PsO diagnosis preceding IL‐inhibiting biologic treatment and ≥1 post‐induction maintenance claim (index date) with sufficient data availability from January 2014 to May 2022. Patients with non‐persistence were excluded. Expected daily dose (EDD) was calculated as the recommended maintenance dose divided by the treatment interval. Dose escalation was defined as ≥2 claims showing a ≥20% increase in the observed average daily dose (ADD) over the EDD (with sensitivities requiring ≥1 claim and ≥30%). Significant differences were tested using multivariable regressions. The study included 982 unique patients treated with brodalumab (BRO; n = 104), guselkumab (GUS; n = 207), ixekizumab (IXE; n = 159), risankizumab (RIS; n = 135), secukinumab (SEC; n = 215) and ustekinumab (UST; n = 196). Within 12 months, dose escalation was observed for all IL‐inhibiting biologics other than GUS and RIS: 44.4% for UST, 37.2% for IXE, 3.4% for SEC and 1.4% for BRO. In multivariable‐adjusted analyses, odds of dose escalation were significantly lower for all products relative to UST. In sensitivities, escalation was observed for all products except RIS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
- AbbVie Inc., North Chicago, Illinois, USA.
- AbbVie GK, Tokyo, Japan.
- Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt am Main, Germany.
- Medicus Economics, LLC, Milton, Massachusetts, USA.
- Department of Dermatology, IIB SANTPAU, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
ORCID-Profile: Yayoi Tada, Ahmed M Soliman, Kanako Ishii, Shinichi Imafuku
Förderung
- AbbVie Inc
- AbbVie
Zitieren
APA
Tada, Y., Soliman, A. M., Ishii, K., Sakuma, R., Pinter, A., Davis, M., Nunag, D., Buessing, M., Puig, L., & Imafuku, S. (2024). Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan. Experimental Dermatology. https://doi.org/10.1111/exd.15067
Vancouver
Tada Y, Soliman AM, Ishii K, Sakuma R, Pinter A, Davis M, et al. Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan. Experimental Dermatology. 2024. doi:10.1111/exd.15067
BibTeX
@article{Tada2024,
author = {Tada, Yayoi and Soliman, Ahmed M and Ishii, Kanako and Sakuma, Ryuta and Pinter, Andreas and Davis, Matthew and Nunag, Dominic and Buessing, Marric and Puig, Luis and Imafuku, Shinichi},
title = {Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan},
journal = {Experimental Dermatology},
year = {2024},
doi = {10.1111/exd.15067}
}
EUVIMED